StockData
Scienture Holdings, Inc. logo

Scienture Holdings, Inc. (SCNX) stock

SCNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$2.76−0.23 (-7.69%)

Close on Nov 17, 2026Market cap $113.34MP/E –Yield –

Scienture r&d expenses

Research and development expenses are spending on new products and technology.

Scienture's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.50M, down 31.6% year over year. For fiscal 2025 it was $1.96M, down 12.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.96M-12.5%
FY2024Dec 31, 2024$2.24M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.17M+38.3%
Q1 FY2026Mar 31, 2026$793.98K+38.2%
Q4 FY2025Dec 31, 2025$368.70K-62.5%
Q3 FY2025Sep 30, 2025$169.34K-86.5%
Q2 FY2025Jun 30, 2025$843.55K–
Q1 FY2025Mar 31, 2025$574.68K–
Q4 FY2024Dec 31, 2024$982.71K–
Q3 FY2024Sep 30, 2024$1.25M–

More Scienture figures

See a number that looks wrong?